Literature DB >> 31659944

The Use of Conformational Restriction in Medicinal Chemistry.

Pedro de Sena M Pinheiro1,2, Daniel A Rodrigues1,3, Rodolfo do Couto Maia1, Sreekanth Thota1,4, Carlos A M Fraga1,2,3.   

Abstract

During the early preclinical phase, from hit identification and optimization to a lead compound, several medicinal chemistry strategies can be used to improve potency and/or selectivity. The conformational restriction is one of these approaches. It consists of introducing some specific structural constraints in a lead candidate to reduce the overall number of possible conformations in order to favor the adoption of a bioactive conformation and, as a consequence, molecular recognition by the target receptor. In this work, we focused on the application of the conformational restriction strategy in the last five years for the optimization of hits and/or leads of several important classes of therapeutic targets in the drug discovery field. Thus, we recognize the importance of several kinase inhibitors to the current landscape of drug development for cancer therapy and the use of G-protein Coupled Receptor (GPCR) modulators. Several other targets are also highlighted, such as the class of epigenetic drugs. Therefore, the possibility of exploiting conformational restriction as a tool to increase the potency and selectivity and promote changes in the intrinsic activity of some ligands intended to act on many different targets makes this strategy of structural modification valuable for the discovery of novel drug candidates. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Annulation; Constraint; Cyclization; G-protein coupled receptor; Hit-to-lead; Kinase; Restriction; Thermodynamics.

Mesh:

Substances:

Year:  2019        PMID: 31659944     DOI: 10.2174/1568026619666190712205025

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  2 in total

1.  MegaSyn: Integrating Generative Molecular Design, Automated Analog Designer, and Synthetic Viability Prediction.

Authors:  Fabio Urbina; Christopher T Lowden; J Christopher Culberson; Sean Ekins
Journal:  ACS Omega       Date:  2022-05-27

2.  Design, Synthesis and Pharmacological Evaluation of Novel Conformationally Restricted N-arylpiperazine Derivatives Characterized as D2/D3 Receptor Ligands, Candidates for the Treatment of Neurodegenerative Diseases.

Authors:  Thayssa Tavares da Silva Cunha; Rafaela Ribeiro Silva; Daniel Alencar Rodrigues; Pedro de Sena Murteira Pinheiro; Thales Kronenberger; Carlos Maurício R Sant'Anna; François Noël; Carlos Alberto Manssour Fraga
Journal:  Biomolecules       Date:  2022-08-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.